Saturday, December 1 & Inflammatory Breast Cancer...

Inflammatory Breast Cancer ConferenceThird International Saturday, December 1 &

Sunday, December 2, 2012

SOFITEL PHILADELPHIA120 South 17th Street

Philadelphia, PA 19103

teach it • treat it • beat it • teach it • treat it • beat it • teach it • treat it • beat it

At the time of publication, the following have provided educational grants to partially support this activity: Dompé, Foundation Medicine,

Inflammatory Breast Cancer Network, Inflammatory Breast Cancer Research Foundation, The Inflammatory Breast Cancer Foundation DBA The Erase IBC Foundation.

Sponsored by:

STATEMENT OF NEED

Inflammatory Breast Cancer (IBC) is the most aggressive form of breast cancer. IBC is frequently misdiagnosed as an infection and valuable time may be wasted in efforts to correctly diagnose IBC. There is rarely a lump and usually cannot be detected on ultrasounds; mammograms are often painful and difficult for these patients. It is very important to distinguish IBC from other types of breast cancer because there are major differences in its symptoms, prognosis, and treatment. Although IBC is uncommon, the aggressive nature necessitates early diagnosis to provide optimum care for these patients.

The International Inflammatory Breast Cancer Conference is designed as a forum for the global IBC community of doctors and researchers to address the gaps in our understanding of the etiological factors, molecular phenotypes and therapeutic options for patients with IBC. Clinicians are uncertain about the most appropriate course of management for these patients, yet timing is critical. The goals of the 3rd International Inflammatory Breast Cancer Conference are to help physicians translate research findings into more effective prevention, improved risk identification, more consistent criteria that results in earlier diagnosis and improved management of patients with IBC so that more women can be diagnosed earlier and live longer with better quality of life than in the past. The educational planning committees seek to address barriers that hinder patients from participating in clinical trials. In addition, the planning committees want to address barriers to getting patients onto clinical trials. Another goal is to develop consensus guidelines and provide strategies to help physicians integrate findings into practice with improved patient outcomes. Multiple educational methods, including Lectures, Question-and-Answer Sessions, Roundtable Discussions, Case Scenarios and Posters, will be used to accommodate individual learning styles.

OBJECTIVES

After completing this activity, learners should be able to:1. Recognize the potential effect of environmental factors,

including rural settings, bacteria and virus, on development of inflammatory breast cancer (IBC) in order to determine potential ways to prevent occurrence of IBC and counsel patients about these epidemiologic findings.

2. Define molecular signatures or specific biomarker expression that separate IBC from other forms of breast cancer and integrate these into management of these patients to improve diagnosis, select better treatments that will affect outcomes, reduce rate of recurrence and improve survival rates.

3. Identify patients with IBC and high risk of recurrence so that appropriate monitoring and screening strategies can be implemented.

4. Translate research findings into clinical practice to improve the early diagnosis and treatment of patients with IBC and improve patient access to early diagnosis and treatment.

5. Integrate into clinical practice consensus guidelines for identifying risk factors, screening, diagnosing and treating patients at risk for IBC or those presenting with the disease.

6. Discuss current diagnostic guidelines with radiologists and pathologists to improve the screening and diagnosis of those with suspected or confirmed IBC.

7. Analyze new developments in IBC research and currently available clinical trials and when clinically relevant, include this information in discussions with patients to foster accrual to clinical trials.

8. Translate new knowledge about the risk factors, screening, diagnosis and treatment of IBC to patients in terms that patients can understand.

9. Increase dialogue between physicians and researchers to identify relevant areas that need to be translated from bench to bedside.

teach it • treat it • beat it • teach it • treat it • beat it • teach it • treat it • beat itThird International Inflammatory Breast Cancer Conference

TARGET AUDIENCEThis program is designed for medical, surgical, and radiation oncologists, radiologists, pathologists, fellows, residents, physician assistants, advanced practice clinicians, nurses and allied health professionals involved in the management of patients with inflammatory breast cancer (IBC); Researchers with a research interest in IBC; and Patient Advocates for IBC. Gynecologists, family and general physicians and internists who manage patients with IBC may find the program beneficial.

ACCREDITATION STATEMENTContinuing Medical Education: The Institute for Cancer Research is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Continuing Nursing Education: Fox Chase Cancer Center is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.Accredited status refers only to its CNE activities and does not imply ANCC-COA/PSNA approval or endorsement of any commercial products. Successful completion of this educational activity requires return of the program validation form indicating sessions attended and completion and return of the program evaluation form.

DESIGNATION STATEMENTContinuing Medical Education: The Institute for Cancer Research designates this educational activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education: The Fox Chase Cancer Center designates this live activity for a maximum of 9.25 continuing nursing education contact hours. Registered nurses should claim only the credit commensurate with the extent of their participation in the activity.

INQUIRIESOffice of Continuing Medical Education, Fox Chase Cancer CenterTelephone: 215-728-5358; Fax: 215-214-8908; E-mail: [email protected]

FOX CHASE Call: 215-728-5358CANCER CENTER Fax: 215-214-8908Philadelphia, PA 19111 www.foxchase.org


PROGRAM

Saturday, December 1, 2012

1:00-5:00 pm REGISTRATION & POSTER SET-UP

5:00-5:30 pm OPENING Session Chairs: Massimo Cristofanilli, MD and Kenneth van Golen, PhD Margaret Foti, PhD, MD American Association for Cancer Research Frances M. Visco, JD National Breast Cancer Coalition Elaine Grobman Philadelphia Affiliate of Susan G. Komen for the Cure Senator Timothy Z. Jennings New Mexico State Senate

5:30-6:30 pm PLENARY LECTURE: MYC AND CANCER: EVOLVING CONCEPTS IN TUMOR METABOLISM Session Chairs: Massimo Cristofanilli, MD and Kenneth van Golen, PhD Chi Van Dang, MD, PhD John H. Glick, MD Abramson Cancer Center Director’s Professor Director Abramson Cancer Center of the University of Pennsylvania

6:30-7:30 pm SESSION EPIDEMIOLOGY OF IBC: NEW RISK FACTORS Session Chairs: Melissa Bondy, PhD and Amr Soliman, MD, PhD

6:30-7:00 pm Current Epidemiologic Studies: Advances and Obstacles Paul Levine, MD The George Washington University School of Medicine

7:00-7:10 pm Q & A


PROGRAM

Saturday, December 1, 2012 (Continuted)

ABSTRACTS

7:10-7:25 pm Incidence of mouse mammary tumor virus-like variant sequences in inflammatory breast cancer Hugo Arias-Pulido, PhD The University of New Mexico Cancer Center7:25-7:30 pm Q & A

7:30-7:45 pm Risk factors for inflammatory breast cancer and other invasive breast cancers Catherine Schairer, PhD The National Cancer Institute

7:45-7:50 pm Q & A

8:00-8:45 pm ADVOCATE SESSION Session Chair: Valerie Fraser, IBC Survivor/Research Advocate and President, Michigan Breast Cancer Coalition

8:00-9:30 pm RECEPTION & POSTER DISPLAY

Sunday, December 2, 2012

7:30-8:30 am REGISTRATION, CONTINENTAL BREAKFAST & POSTER DISPLAY

8:30-10:30 am CONCURRENT SESSION 1: BREAKING NEWS: IBC RESEARCH UPDATE Session Chair: Kenneth van Golen, PhD and Steven Van Laere, MSc, PhD

8:30-9:00 am New Concepts in the Biology and Therapy of Brain Metastases of Breast Cancer Patricia S. Steeg, PhD The National Cancer Institute

9:00-9:10 am Q & A


PROGRAM

Sunday, December 2, 2012 (Continuted)

ABSTRACTS

9:10-9:20 am AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), ERBB2 (HER2), and ERBB3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models Zhaomei Mu, MD Fox Chase Cancer Center9:20-9:25 am Q & A

9:25-9:35 am Inflammatory response initiated by COX-2 promotes epithelial-mesenchymal transition and a stem-like cell population in EGFR-overexpressing inflammatory breast cancer Naoto T. Ueno, MD, PhD, FACP The University of Texas MD Anderson Cancer Center9:35-9:40 am Q & A

9:40-9:50 am Anaplastic lymphoma kinase in breast tumor cells induces formation of tumor emboli encircled by lymphatic vessels and a pro-inflammatory cytokine cascade regulated by interleukin-17 Fredika Robertson, PhD The University of Texas MD Anderson Cancer Center9:50-9:55 am Q & A

9:55-10:05 am Signaling and phenotypic changes associated with PDGFRα targeting in inflammatory breast cancer Madhura Joglekar, BS The University of Delaware10:05-10:10 am Q & A

10:10-10:20 am Peptide based molecular targeting of inflammatory breast cancer Bedrich L. Eckhardt, PhD The University of Texas MD Anderson Cancer Center10:20-10:25 am Q & A


PROGRAM


8:30-10:30 am CONCURRENT SESSION 2: NURSE, ALLIED HEALTH PROFESSIONAL & ADVOCATES EDUCATIONAL SESSION Session Chairs: Bernadette Ciukurescu,BSN,RN-BC & Bonnie Miller,RN,BSN,OCN,FAAMA

8:30-9:45 am Inflammatory Breast Cancer: Past , Present and Future Pam Alizadeh, RN, Onc NP, MS, AOCN, CBCN The University of Texas MD Anderson Cancer Center

9:45-10:30 am PANEL DISCUSSION Pam Alizadeh, RN, Onc NP, MS, AOCN, CBCN The University of Texas MD Anderson Cancer Center Valerie Fraser, IBC Survivor/Research Advocate and President Michigan Breast Cancer Coalition Jessie Schol, RN, BSN, OCN Fox Chase Cancer Center

10:30-11:00 am BREAK & POSTER DISPLAY

11:00-1:00 pm SESSION 3: EVOLVING IBC TREATMENTS: FROM BENCH TO BEDSIDE Session Chairs: Massimo Cristofanilli, MD and Patrice Viens, MD

11:00-11:30 am Evolving HER-2 Targeted Therapies in Breast Cancer: Lessons for IBC Neil Spector, MD Duke Cancer Institute

11:30-11:40 am Q & A ABSTRACTS

11:40-11:55 am Response to neoadjuvant systemic therapy (NST) in inflammatory breast cancer (IBC) according to estrogen receptor (ER) and HER2 expression Hiroko Masuda, MD, PhD The University of Texas MD Anderson Cancer Center11:55-12:00pm Q & A


PROGRAM


12:00-12:15pm Epidemiological risk factors and normal breast tissue markers in inflammatory breast cancer Rachel L. Atkinson, PhD The University of Texas MD Anderson Cancer Center12:15-12:20pm Q & A

12:20-12:35pm Implications of prevalence of anaplastic lymphoma kinase in inflammatory breast cancer Fredika Robertson, PhD The University of Texas MD Anderson Cancer Center12:35-12:40pm Q & A

12:40-12:55pm Mutation discordance between tissue sources from the same patient R. Katherine Alpaugh, PhD Fox Chase Cancer Center12:55-1:00pm Q & A

1:00-2:00 pm LUNCH & POSTER DISPLAY

2:00-3:00 pm SESSION 4: LOCOREGIONAL THERAPIES: UNANSWERED QUESTIONS Session Chairs: Wendy Woodward, MD, PhD & Prof. Francois Bertucci, MD, PhD

2:00-2:30 pm Evolving Locoregional Radiation Therapy Modalities for IBC Wendy Woodward, MD, PhD The University of Texas MD Anderson Cancer Center2:30-2:40 pm Q & A


PROGRAM


ABSTRACTS

2:40-2:55 pm Assessment of residual disease using mammography (MG), sonography (US), and magnetic resonance imaging (MRI) in patients (pts) with inflammatory breast cancer (IBC) who received neoadjuvant chemotherapy (NAC) H. Carisa Le-Petross, MD The University of Texas MD Anderson Cancer Center2:55-3:00 pm Q & A

3:00-3:30 pm BREAK & POSTER DISPLAY

3:30-4:30 pm SESSION 5: TISSUE LABORATORY AND IMAGING: DETECTION, DISCOVERY AND MONITORING Session Chairs: Sanford H. Barsky, MD and Luc Y. Dirix, MD

3:30-4:00 pm Protein Micoarray: Molecular Dianostics for Discovery and Therapeutic Targeting Emanuel F. Petricoin, PhD George Mason University4:00-4:10 pm Q & A

ABSTRACTS

4:10-4:25 pm CTC and CEC in IBC patients during neoadjuvant chemotherapy combine with bevacizumab and trastuzumab according to HER2+ status: Finding of the BEVERLY 01 & 02 trials Francois-Clement Bidard, MD, PhD Institut Curie4:25-4:30 pm Q & A

4:30-6:00 pm ROUNDTABLE DISCUSSION: LESSONS LEARNED AND BEYOND

6:00-7:00 pm CLOSING


REGISTRATION & PAYMENT: (Limit 200 attendees.)

Registration Fees (includes e-handouts; Dec. 1: Reception; Dec. 2: Breakfast, Breaks, Luncheon)

Before November 19 After November 19• Physicians/PA’s/Nurses/Advanced Practice Clinicians/ Other Health Professionals/Researchers $350 $450 • Fellows/Residents/Students $ 75 $125• Patient Advocates $ 75 $125• FCCC Partner (FCCC Partner affiliation required.) $250 $300• Guest, Saturday Evening Reception (Guest name/registration required.) $ 50 $ 50

Registration Deadline: November 19, 2012 Cancellations received prior to November 19, 2012, will be refunded in full.

CHECK Payable to Institute for Cancer Research; Mail to: Norma Gentner, Office of CME, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111

CREDIT CARD payment (Visa, MasterCard, Discover) available at www.fccc.edu/CMEregistration

INQUIRIESOffice of Continuing Medical Education, Fox Chase Cancer CenterTelephone: 215-728-5358; Fax: 215-214-8908; E-mail: [email protected]

ACCOMMODATIONS (Fox Chase Cancer Center will not accept responsibility for hotel reservations.) A block of rooms has been reserved for conference attendees at the:

SOFITEL PHILADELPHIA, 120 South 17th Street, Philadelphia, PA 19103Reservations: (See Hotel Reservation Form)• Phone: 1-877-411-7634 or 215-569-8300• Website: www.sofitel-philadelphia.com • Complete the Hotel Reservation Form and Fax to: 215-564-7453

Attention: Reservations Department (John Marshall)

Rate: $179 single or double occupancy. (Applicable state and local taxes, currently 15.2%, will be added.) Ask for Group Reservations and identify yourself as a member of the Third International Inflammatory Breast Cancer Conference.


Deadline: The room block is available until Monday, November 5, 2012 or until the room block is full. Reservations received after that date will be confirmed if space is available and at published hotel guest room rates. We suggest making hotel reservations as early as possible.

THIRD INTERNATIONAL INFLAMMATORY BREAST CANCER CONFERENCEREGISTRATION FORM

Name _________________________________________________________________Degree _______________________ Medical Specialty ___________________________(Please print/type name and degree as you would like them to appear on your nametag/certificate.)

Institution/Affiliation _____________________________________________________________________________________________________________________________

Preferred Mailing Address _________________________________________________________________________________________________________________________

City _______________________________________ State ______________________ Zip _____________________________________________________________________

Daytime Phone _____________________________ Fax ________________________ E-mail __________________________________________________________________________________

❏ If you are Fellow/Resident/Student, indicate Medical School __________________________________________________________________________________________________________ (Required for Fellow/Resident pricing.)

Specify questions/issues you would like speakers to address.

REGISTRATION & PAYMENT (Limit 200 attendees): Registration Fees (includes e-handouts; Dec. 1: Reception; Dec. 2: Breakfast, Breaks, Luncheon)

Before AfterPlease circle your choice: November 19 November 19• Physicians/PA’s/Nurses/Advanced Practice Clinicians/

Other health professionals/Researchers $350 $450 • Fellows/Residents/Students $ 75 $125• Patient Advocates $ 75 $125• FCCC Partner (FCCC Partner affiliation required.) $250 $300

FCCCP Institution ___________________________________________________ • Guest, Saturday Evening Reception $ 50 $ 50

Guest name required ________________________________________________Registration Deadline: November 19, 2012 Cancellations received prior to November 19, 2012, will be refunded in full.

❏ CHECK Payable to Institute for Cancer Research; Mail to: Norma Gentner, Office of CME, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111

❏ CREDIT CARD payment (Visa, MasterCard, Discover) available at www.fccc.edu/CMEregistration

SPECIAL NEEDSADA Requirements: If you require auxiliary aids or services as identified in the Americans with Disabilities Act, please note your needs. (Specify) Dietary Requirements: ❏ Kosher ❏ Vegetarian ❏ Other (Specify)

INQUIRIES: Office of CME, Fox Chase Cancer Center, Phone: 215-728-5358; Fax: 215-214-8908; E-mail: [email protected]


Sponsored by:

THIRD INTERNATIONAL INFLAMMATORY BREAST CANCER CONFERENCEHOTEL RESERVATION FORM

SOFITEL PHILADELPHIA120 South 17th Street, Philadelphia, PA 19103

Hotel Reservations (Note: Fox Chase Cancer Center will not accept responsibility for hotel reservations.)• Phone: 1-877-411-7634 or 215-569-8300• Website: www.sofitel-philadelphia.com • Complete this form and Fax to: 215-564-7453 Attention: Reservations Department (John Marshall)

Rate: $179 single or double occupancy. (Applicable state and local taxes, currently 15.2%, will be added.)Ask for Group Reservations and identify yourself as a member of the Third International Inflammatory Breast Cancer Conference.

Deadline: The room block is available until Monday, November 5, 2012 or until the room block is full. Reservations received after that date will be confirmed if space is available and at published hotel guest room rates. We suggest making hotel reservations as early as possible.

GUEST INFORMATION:

Last Name_________________________________________________________________________________________________________________________________________ First Name____________________________________________________________________ Title_________________________________________________________________

Company____________________________________________________________________________________________________________________________________________ Address_____________________________City _________________________________________________________________ State _________________ Zip ________________

Daytime Phone __________________________ Fax _____________ E-mail ___________________________________________________________________________________

RESERVATION SPECIFICS:

Arrival_________________________________________ Departure_________________________________________ Arrival Time_________________________________________

Room Type:_______________________________________________ Number of Rooms____________________________________________________________________________ ❏ KGB (Superior King ) $179 Note: Other room types available at higher rate.

No. of Guests __________________________________________________________________________________ Rate ______________________________________________

Guarantee Method _________________________________________________________________________________________________________________________________

Credit Card # _____________________________________________________ Exp. Date ___________________________________________

Special Needs/Requests:__________________________________________________________________________________________________


Sponsored by:

Saturday, December 1 & Inflammatory Breast Cancer...

Documents

Transcript of Saturday, December 1 & Inflammatory Breast Cancer...